Opinion

Aaron Goodman: My prediction (American Society of Hematology 2023)

Photo from Aaron Goodman/X

Dec 9, 2023, 16:37

Aaron Goodman: My prediction (American Society of Hematology 2023)

Aaron Goodman shared a post on X/Twitter:

“My prediction is the plenary session at American Society of Hematology in 2033 will be 10 drugs vs 9 drugs in myeloma end point Minimal Residual Disease (MRD). IKRd vs KRd in newly diagnosed multiple myeloma.

For details, click here.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman American Society of Hematology cancer Minimal Residual Disease (MRD) multiple myeloma National Comprehensive Cancer Network OncoDaily Oncology University of California

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage